Iressa Expanded Access Could Have Been Designed To Bolster Efficacy
Executive Summary
AstraZeneca's expanded access program for Iressa could have been designed to bolster efficacy data from pivotal trials, FDA Oncologic Drug Products Division Director Richard Pazdur, MD, suggested